Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.42 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.40 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28471721 | 0.86 | CES2 (0.48) | CES2SMN1; SMN2TP53MAPTRAB9A | |
| SCHEMBL107636 | 0.86 | CSNK2A1 (0.52) | CES2SMN1; SMN2TP53MAPTRAB9A | |
| SCHEMBL18354210 | 0.85 | CES2 (0.47) | CES2SMN1; SMN2TP53MAPTRAB9A | |
| SCHEMBL4620600 | 0.83 | CES2 (0.46) | CES2SMN1; SMN2TP53MAPTRAB9A | |
| SCHEMBL108796 | 0.83 | SMN1; SMN2 (0.47) | CES2SMN1; SMN2TP53MAPTRAB9A | |
| SCHEMBL26020411 | 0.81 | CES2 (0.49) | CES2SMN1; SMN2TP53MAPTRAB9A | |
| SCHEMBL22728372 | 0.81 | PDE3B (0.44) | CES2SMN1; SMN2TP53MAPTRAB9A | |
| SCHEMBL30481870 | 0.81 | CES2 (0.72) | CES2MAPTALDH1A1HTTKDM4E | |
| SCHEMBL31252817 | 0.81 | ESRRG (0.48) | CES2MAPTP2RX1ALDH1A1KMT2A | |
| SCHEMBL31138870 | 0.81 | KIF11 (0.51) | CES2MAPTRAB9AKMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951022-B2 | Method for producing 4,4,7-trifluoro-1,2,3,4-tetrahydro-5H-1-benzazepine compound and intermediate used in the method | TACURION (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170158639-A1 | METHOD FOR PRODUCING 4,4,7-TRIFLUORO-1,2,3,4-TATRAHYDRO-5H-1-BENZAZEPINE COMPOUND AND INTERMEDIATE USED IN THE METHOD | TACURION (US) | 2017-06-08 | — | — | US | disclosed |
| US-9598373-B2 | Method for producing 4,4,7-trifluoro-1,2,3,4-tetrahydro-5H-1-benzazepine compound and intermediate used in the method | TACURION (US) | 2017-03-21 | — | — | US | disclosed |
| US-20150141641-A1 | METHOD FOR PRODUCING 4,4,7-TRIFLUORO-1,2,3,4-TETRAHYDRO-5H-1-BENZAZEPINE COMPOUND AND INTERMEDIATE USED IN THE METHOD | ASTELLAS PHARMA INC. (JP) | 2015-05-21 | — | — | US | disclosed |
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| WO-2010038465-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | 旭化成ファーマ株式会社 (JP) | 2010-04-08 | — | — | WO | disclosed |
| EP-0735142-B1 | Process for producing (R)-styrene oxides | SUMIKA FINE CHEMICALS CO LTD (JP) | 2001-10-24 | — | — | EP | disclosed |
| US-5717116-A | TREATING A MIXTURE OF PHENYLHALOGENOMETHYLCARBINOLS WITH A LIPASE IN THE PRESENCE OF A CARBOXYLATE FOLLOWED BY CYCLIZATION WITH A BASE | SUMIKA FINE CHEMICALS COMPANY, LIMITED (JP) | 1998-02-10 | — | — | US | disclosed |
| EP-0735142-A2 | Process for producing (R)-styrene oxides | SUMIKA FINE CHEMICAL COMPANY, LTD. (JP) | 1996-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141641-A1 | METHOD FOR PRODUCING 4,4,7-TRIFLUORO-1,2,3,4-TETRAHYDRO-5H-1-BENZAZEPINE COMPOUND AND INTERMEDIATE USED IN THE METHOD | AVPR2, AVPR1A, AVPR1B | CES2 3104/4885SMN1; SMN2 2727/4885TP53 4354/4885 |
| US-20170158639-A1 | METHOD FOR PRODUCING 4,4,7-TRIFLUORO-1,2,3,4-TATRAHYDRO-5H-1-BENZAZEPINE COMPOUND AND INTERMEDIATE USED IN THE METHOD | AVPR2, AVPR1A, AVPR1B | CES2 2153/4885SMN1; SMN2 2939/4885TP53 4155/4885 |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | RELA, NFKBIA, NFKB2 | CES2 3530/4885SMN1; SMN2 3014/4885TP53 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.